



Dicot Pharma has submitted clinical trial application for phase 2a trial

Uppsala, Sweden, July 8, 2024. Dicot Pharma announces today that a clinical trial application for a phase 2a trial with the drug candidate LIB-01, has been submitted. The trial is planned to start in the fourth quarter of 2024 as previously communicated. The trial is fully funded with the amount secured in advance in the announced rights issue that the company intends to carry out in August.

Dicot is developing a new potency drug with the aim to treat erectile dysfunction better than existing drugs on the market. With good results from the company's recently completed phase 1 trial, a clinical trial application for a phase 2a trial has now been submitted. It is a so-called "proof of concept", with the main objective of demonstrating that LIB-01 can improve erectile function in patients with erectile dysfunction. The trial, which is placebo-controlled and double-blind, will include approximately 140 participants and will be conducted at clinics in Sweden, Denmark and the Netherlands. The start of the trial is planned for the fourth quarter of 2024, when the first patient is expected to start treatment with LIB-01. Through the commitments obtained in advance in the rights issue that the company intends to carry out in August, the trial is fully financed.

"We continue to focus on driving the drug development of LIB-01 forward. With the submitted clinical trial application and the capital secured from the upcoming rights issue we can continue to maintain a high pace and in accordance with our schedule. We are very much looking forward to starting this exciting development phase and to keeping you updated with information about the study", comments Elin Trampe, CEO at Dicot Pharma.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 6,100 shareholders. For more information, please visit www.dicotpharma.com.

